Cargando…
PB2118: TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA.
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429027/ http://dx.doi.org/10.1097/01.HS9.0000975244.51467.aa |
| _version_ | 1785090612898299904 |
|---|---|
| author | Monsen, Hedda Norseth, Hanne Marie Remen, Nora Abrahamsen, Ingerid Lysén, Anna Schjesvold, Fredik |
| author_facet | Monsen, Hedda Norseth, Hanne Marie Remen, Nora Abrahamsen, Ingerid Lysén, Anna Schjesvold, Fredik |
| author_sort | Monsen, Hedda |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429027 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104290272023-08-17 PB2118: TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA. Monsen, Hedda Norseth, Hanne Marie Remen, Nora Abrahamsen, Ingerid Lysén, Anna Schjesvold, Fredik Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429027/ http://dx.doi.org/10.1097/01.HS9.0000975244.51467.aa Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Monsen, Hedda Norseth, Hanne Marie Remen, Nora Abrahamsen, Ingerid Lysén, Anna Schjesvold, Fredik PB2118: TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA. |
| title | PB2118: TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA. |
| title_full | PB2118: TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA. |
| title_fullStr | PB2118: TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA. |
| title_full_unstemmed | PB2118: TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA. |
| title_short | PB2118: TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA. |
| title_sort | pb2118: tg01-study: a phase 1/2 study with tg01 immunotherapy vaccination in patients with confirmed nras/kras mutation on codon 12/13 and multiple myeloma or high-risk smoldering myeloma. |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429027/ http://dx.doi.org/10.1097/01.HS9.0000975244.51467.aa |
| work_keys_str_mv | AT monsenhedda pb2118tg01studyaphase12studywithtg01immunotherapyvaccinationinpatientswithconfirmednraskrasmutationoncodon1213andmultiplemyelomaorhighrisksmolderingmyeloma AT norsethhannemarie pb2118tg01studyaphase12studywithtg01immunotherapyvaccinationinpatientswithconfirmednraskrasmutationoncodon1213andmultiplemyelomaorhighrisksmolderingmyeloma AT remennora pb2118tg01studyaphase12studywithtg01immunotherapyvaccinationinpatientswithconfirmednraskrasmutationoncodon1213andmultiplemyelomaorhighrisksmolderingmyeloma AT abrahamseningerid pb2118tg01studyaphase12studywithtg01immunotherapyvaccinationinpatientswithconfirmednraskrasmutationoncodon1213andmultiplemyelomaorhighrisksmolderingmyeloma AT lysenanna pb2118tg01studyaphase12studywithtg01immunotherapyvaccinationinpatientswithconfirmednraskrasmutationoncodon1213andmultiplemyelomaorhighrisksmolderingmyeloma AT schjesvoldfredik pb2118tg01studyaphase12studywithtg01immunotherapyvaccinationinpatientswithconfirmednraskrasmutationoncodon1213andmultiplemyelomaorhighrisksmolderingmyeloma |